IP Library Granted Patent US 8,759,003
Granted Patent B2
US 8,759,003 · App. 13/032,464 · Granted Jun 24, 2014

Detection of West Nile virus nucleic acids in the viral 3′ non-coding region

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,003
App. No.
13/032,464
Granted
Jun 24, 2014
Kind
B2
Abstract

Methods for detecting flavivirus nucleic acids. Particularly described are methods for detecting West Nile virus nucleic acids in the 3′ non-coding region.

Claims (25)

1. A method of establishing whether a biological sample contains WNV (West Nile virus), said method comprising the steps of:

(a) obtaining nucleic acids from the biological sample;

(b) performing an in vitro nucleic acid amplification reaction that comprises nucleic acids obtained in step (a) as templates,

whereby a nucleic acid strand is synthesized if nucleic acids obtained in step (a) comprise WNV nucleic acids,

wherein one end of said nucleic acid strand terminates with the nucleotide sequence SEQ ID NO:74 or the complement thereof, allowing for substitution of RNA and DNA equivalent bases,

wherein said in vitro nucleic acid amplification reaction comprises an oligonucleotide that is up to 60 nucleotides in length and comprises the base sequence of SEQ ID NO:116 or the complement thereof, and

wherein a nucleic acid duplex comprising said nucleic acid strand and said oligonucleotide is formed by complementary base pairing in said in vitro nucleic acid amplification reaction if said nucleic acid strand was synthesized;

(c) determining whether said nucleic acid duplex formed in said in vitro nucleic acid amplification reaction; and

(d) establishing either that,

(i) the biological sample contains WNV if said nucleic acid duplex is determined to have formed in said in vitro nucleic acid amplification reaction, or

(ii) the biological sample does not contain detectable amounts of WNV if said nucleic acid duplex is not determined to have formed in said in vitro nucleic acid amplification reaction.

2. The method of claim 1 , wherein the complement of SEQ ID NO:74 is a template for enzymatic synthesis of nucleic acid in said in vitro nucleic acid amplification reaction of step (b), and wherein the base sequence of said nucleic acid strand comprises the base uracil in place of the base thymine.

3. The method of claim 1 , wherein the biological sample comprises a product of donated blood.

4. The method of claim 3 , wherein the product of donated blood is selected from the group consisting of: a plasma sample, and a serum sample.

5. The method of claim 3 , wherein step (a) comprises capturing nucleic acids onto magnetically attractable particles.

6. The method of claim 5 , wherein said nucleic acid strand synthesized in step (b) comprises the base uracil in place of the base thymine.

7. The method of claim 3 , wherein the in vitro nucleic acid amplification reaction in step (b) comprises one enzyme that provides both reverse transcriptase and DNA polymerase activities, and does not comprise independent DNA polymerase and reverse transcriptase enzymes.

8. The method of claim 7 , wherein the complement of SEQ ID NO:74 is a template for enzymatic synthesis of nucleic acid in said in vitro nucleic acid amplification reaction of step (b), and wherein the base sequence of said nucleic acid strand comprises the base uracil in place of the base thymine.

9. The method of claim 7 , wherein step (c) comprises determining, while the in vitro nucleic acid amplification reaction is occurring, whether said nucleic acid duplex formed.

10. The method of claim 1 , wherein step (a) comprises capturing nucleic acids onto magnetically attractable particles.

11. The method of claim 10 , wherein the in vitro nucleic acid amplification reaction in step (b) comprises one enzyme that provides both reverse transcriptase and DNA polymerase activities, and does not comprise independent DNA polymerase and reverse transcriptase enzymes.

12. The method of claim 11 , wherein step (c) comprises determining, while the in vitro nucleic acid amplification reaction is occurring, whether said nucleic acid duplex formed.

13. The method of claim 1 , wherein the in vitro nucleic acid amplification reaction in step (b) comprises one enzyme that provides both reverse transcriptase and DNA polymerase activities, and does not comprise independent DNA polymerase and reverse transcriptase enzymes.

14. The method of claim 1 , wherein step (c) comprises performing either fluorimetry or luminometry to quantify any of an optical signal that indicates formation of said nucleic acid duplex.

15. The method of claim 1 , wherein step (c) comprises performing fluorimetry, while the in vitro nucleic acid amplification reaction is occurring, to quantify any of an optical signal that indicates formation of said nucleic acid duplex.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2011
From: LINNEN, JEFFREY M.; POLLNER, REINHOLD B.; WU, WEN; DENNIS, GEOFFREY G.; DARBY, PAUL M.
To: GEN-PROBE INCORPORATED
Reel/Frame 025889/0016 →